Dyadic Price to Free Cash Flow Ratio 2006-2021 | DYAI

Historical price to free cash flow ratio values for Dyadic (DYAI) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Dyadic Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 4.85 0.00
2021-06-30 3.59 $-0.25 0.00
2021-03-31 5.49 $-0.24 0.00
2020-12-31 5.38 $-0.24 0.00
2020-09-30 7.57 $-0.25 0.00
2020-06-30 8.66 $-0.25 0.00
2020-03-31 5.20 $-0.29 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.136B $0.002B
Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00